- Home
- TME vs ONC Comparison
TME vs ONC Comparison
Compare TME & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TME
- ONC
- Stock Information
- Founded
- TME N/A
- ONC 2010
- Country
- TME China
- ONC Switzerland
- Employees
- TME N/A
- ONC N/A
- Industry
- TME Broadcasting
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- TME Consumer Discretionary
- ONC Health Care
- Exchange
- TME Nasdaq
- ONC Nasdaq
- Market Cap
- TME 28.5B
- ONC 26.9B
- IPO Year
- TME 2018
- ONC N/A
- Fundamental
- Price
- TME $19.45
- ONC $245.49
- Analyst Decision
- TME Strong Buy
- ONC Strong Buy
- Analyst Count
- TME 6
- ONC 9
- Target Price
- TME $15.00
- ONC $325.56
- AVG Volume (30 Days)
- TME 6.5M
- ONC 367.8K
- Earning Date
- TME 08-12-2025
- ONC 08-06-2025
- Dividend Yield
- TME 0.93%
- ONC N/A
- EPS Growth
- TME 84.42
- ONC N/A
- EPS
- TME 0.84
- ONC N/A
- Revenue
- TME $3,994,901,125.00
- ONC $4,175,868,000.00
- Revenue This Year
- TME $10.99
- ONC $869.15
- Revenue Next Year
- TME $11.82
- ONC $19.07
- P/E Ratio
- TME $22.87
- ONC N/A
- Revenue Growth
- TME 5.35
- ONC 51.16
- 52 Week Low
- TME $9.41
- ONC $142.00
- 52 Week High
- TME $19.58
- ONC $287.88
- Technical
- Relative Strength Index (RSI)
- TME 63.63
- ONC N/A
- Support Level
- TME $18.88
- ONC N/A
- Resistance Level
- TME $19.58
- ONC N/A
- Average True Range (ATR)
- TME 0.45
- ONC 0.00
- MACD
- TME -0.06
- ONC 0.00
- Stochastic Oscillator
- TME 70.83
- ONC 0.00
About TME Tencent Music Entertainment Group each representing two
Tencent Music is the largest online music streaming platform in China, established in 2016 through the merger of QQ Music, Kuwo Music, and Kugou Music. Tencent, its largest shareholder, holds over 50% of the shares and more than 90% of the voting rights. Beyond streaming services, Tencent Music generates revenue through a diverse range of offerings, including podcasts, livestreaming, concerts, and karaoke.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.